Drug InfoNet.com
DrugInfoNet Home Page FAQ Drug Info Disease Info Manufacturer Info Health Care News Health Info Become Panelist Health Care Orgs Medical References Government Sites Hospital Sites Medical Schools
Search
Powered By HealthLine
Health Tools
 Heart Healthy Diet
 Ideal Body Weight Calculator
 Diet Reviews
 Fitness and Family
 Quiz: Test Your Fitness IQ
 Exercise and Fitness Guide
 Eat Out Smart
 Healthy Cooking
 BMI Calculator
Featured Conditions
 Diet & Exercise
 Stop Smoking
 Food & Fitness
 High Blood Pressure
 Cholesterol
 Heart
Resources
Healthscout News
3D Health Animations
Health Videos
Quizzes & Tools
Health Encyclopedia
Library & Communities
News Archive
Drug Library
Find a Therapist
Enter City or Zip Code:
Powered by Psychology Today



Channels
Home |  Today | Women| Men| Kids| Seniors| Diseases| Addictions| Sex & Relationships| Diet, Fitness, Looks| Alternative Medicine
 Printer Friendly  Send to a Friend

Drug Cures Osteoporosis in Mice

Experimental agent targets serotonin in the gut, triggering bone formation


Related Healthscout Videos
 border=
Bone Scaffold: Medicine's Next Big Thing?
Osteoporosis: Not Just a Woman's Disease
Nutrition and Osteoporosis
Critical Nutrition
More...

Related Animations
 border=
Osteoporosis Basics
More...

Related News Articles
 border=
Female Soccer Players May Face Health Problems: Study
Breast Cancer Drug May Weaken Bones, Study Finds
With Calcium, More May Not Be Better
Study Finds Slight Risk of Rare Fractures From Bone Drugs
More...

MONDAY, Feb. 8 (HealthDay News) -- An experimental drug that inhibits serotonin in the gut cured osteoporosis in lab mice and rats, a new study has found.

Previous research has shown that serotonin in the gut hinders bone formation. Most current drugs for osteoporosis only prevent the breakdown of bone; they don't build bone.

Text Continues Below



"New therapies that inhibit the production of serotonin in the gut have the potential to become a [new] class of drugs to be added to the therapeutic arsenal against osteoporosis," study author Dr. Gerard Karsenty, chairman of the department of genetics and development at Columbia University College of Physicians and Surgeons, said in a university news release.

In the new study, published in the Feb. 7 issue of Nature Medicine, small daily doses of the new drug were given by mouth for up to six weeks to rodents with postmenopausal osteoporosis. The treatment prevented osteoporosis from developing or fully cured rodents in which osteoporosis was already present.

While the drug inhibited serotonin in the gut, levels of serotonin remained normal in the rodents' brains. This indicates that the drug didn't enter general circulation and wasn't able to cross the blood-brain barrier, thus greatly reducing the risk of side effects.

"With tens of millions of people worldwide affected by this devastating and debilitating bone loss, there is an urgent need for new treatments that not only stop bone loss but also build new bone. Using these findings, we are working hard to develop this type of treatment for human patients," Karsenty said.

More information

The American College of Rheumatology has more about osteoporosis.



-- Robert Preidt

Copyright © 2010 HealthDay. All rights reserved.
Last updated 2/8/2010

Related Links
 border=
From Healthscout's partner site on diet & exercise, MyDietExercise.com
QUIZ: What's your ideal body weight?
QUIZ: Check your body mass index (BMI) online!
QUIZ: Rate your carbohydrate intake




SOURCE: Columbia University, news release, Feb. 7, 2010


HealthScout is a part of HealthCentral
About Us   Our Blog   Contact Us   Privacy Policy   Terms of Use   Site Map  
Copyright © 2001-2012. The HealthCentralNetwork, Inc. All rights reserved.
Advertising Policy   Editorial Policy Advertise With Us   Anti-Spam Policy   PR Newswire  

FAQ Drug Info Disease Info Manufacturer Info Health Care News Health Info Become Panelist Health Care Orgs Medical References Government Sites Hospital Sites Medical Schools
Contact | Site Map | Search | Disclaimer | Mission Statement

© 1996-2003 DRUG INFONET, Inc. All rights reserved.